Switching to insulin degludec/aspart penfill reusable cartridges in patients with type 2 diabetes mellitus: real-life outcomes
Abstract Aims This study aimed to evaluate the clinical outcomes of switching from disposable insulin delivery pens to reusable insulin pens with a penfill cartridge system for the co-formulation of insulin degludec and insulin aspart (IDegAsp) in patients with type 2 diabetes (T2D) in Türkiye. We a...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | Diabetology & Metabolic Syndrome |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13098-025-01918-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849226079959515136 |
|---|---|
| author | Sezin Dogan Çakır Hatice Deniz Yücel Zeynep Akgül Kızılçay Mine Adaş |
| author_facet | Sezin Dogan Çakır Hatice Deniz Yücel Zeynep Akgül Kızılçay Mine Adaş |
| author_sort | Sezin Dogan Çakır |
| collection | DOAJ |
| description | Abstract Aims This study aimed to evaluate the clinical outcomes of switching from disposable insulin delivery pens to reusable insulin pens with a penfill cartridge system for the co-formulation of insulin degludec and insulin aspart (IDegAsp) in patients with type 2 diabetes (T2D) in Türkiye. We assessed the impact on glycemic control to evaluate the sustainability of this transition. Methods A total of 226 adults with T2D who were initiating or switching to IDegAsp reusable cartridge insulin pens at a tertiary center in Türkiye were followed for 6 months. Data were retrospectively extracted from the medical records at baseline (prior to switching) and at follow-up visits after 3 and 6 months of IDegAsp Penfill reusable cartridges. Results Initiating the IDegAsp reusable cartridge insulin pen in patients who previously used basal-bolus, basal, or premixed insulin therapies with disposable insulin pens was associated with a significant reduction in mean glycated hemoglobin (HbA1c) [mean change -1.0% (95% confidence interval (CI) − 2.2 to − 0.20; p < 0.001)], [− 1.4% (95% CI − 2.3 to − 0.4; p < 0.001)], and [− 0.9% (CI − 1.7 to − 0.1; p < 0.001)]. Switching from IDegAsp disposable insulin pens to the reusable system demonstrated noninferior outcomes [− 0.08% (CI − 0.2 to 0.1; p = 0.629)]. The mean total daily insulin dose and body weight were also significantly lower in patients who were switched from basal-bolus insulin, basal insulin or premixed insulin therapies (p < 0.001 and p < 0.001, respectively). Conclusion Initiating or switching to the IDegAsp reusable pen with the insulin cartridge system in a real-world population of people with T2D in Türkiye was associated with improved or maintained glycemic control. |
| format | Article |
| id | doaj-art-9bcf75c1be1443e6bc95d550fd2dd06d |
| institution | Kabale University |
| issn | 1758-5996 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | BMC |
| record_format | Article |
| series | Diabetology & Metabolic Syndrome |
| spelling | doaj-art-9bcf75c1be1443e6bc95d550fd2dd06d2025-08-24T11:41:42ZengBMCDiabetology & Metabolic Syndrome1758-59962025-08-011711910.1186/s13098-025-01918-ySwitching to insulin degludec/aspart penfill reusable cartridges in patients with type 2 diabetes mellitus: real-life outcomesSezin Dogan Çakır0Hatice Deniz Yücel1Zeynep Akgül Kızılçay2Mine Adaş3Department of Endocrinology and Metabolism, University of Health Sciences, Prof. Dr. Cemil Tascioglu City HospitalDepartment of Endocrinology and Metabolism, University of Health Sciences, Prof. Dr. Cemil Tascioglu City HospitalDepartment of Endocrinology and Metabolism, University of Health Sciences, Prof. Dr. Cemil Tascioglu City HospitalDepartment of Endocrinology and Metabolism, University of Health Sciences, Prof. Dr. Cemil Tascioglu City HospitalAbstract Aims This study aimed to evaluate the clinical outcomes of switching from disposable insulin delivery pens to reusable insulin pens with a penfill cartridge system for the co-formulation of insulin degludec and insulin aspart (IDegAsp) in patients with type 2 diabetes (T2D) in Türkiye. We assessed the impact on glycemic control to evaluate the sustainability of this transition. Methods A total of 226 adults with T2D who were initiating or switching to IDegAsp reusable cartridge insulin pens at a tertiary center in Türkiye were followed for 6 months. Data were retrospectively extracted from the medical records at baseline (prior to switching) and at follow-up visits after 3 and 6 months of IDegAsp Penfill reusable cartridges. Results Initiating the IDegAsp reusable cartridge insulin pen in patients who previously used basal-bolus, basal, or premixed insulin therapies with disposable insulin pens was associated with a significant reduction in mean glycated hemoglobin (HbA1c) [mean change -1.0% (95% confidence interval (CI) − 2.2 to − 0.20; p < 0.001)], [− 1.4% (95% CI − 2.3 to − 0.4; p < 0.001)], and [− 0.9% (CI − 1.7 to − 0.1; p < 0.001)]. Switching from IDegAsp disposable insulin pens to the reusable system demonstrated noninferior outcomes [− 0.08% (CI − 0.2 to 0.1; p = 0.629)]. The mean total daily insulin dose and body weight were also significantly lower in patients who were switched from basal-bolus insulin, basal insulin or premixed insulin therapies (p < 0.001 and p < 0.001, respectively). Conclusion Initiating or switching to the IDegAsp reusable pen with the insulin cartridge system in a real-world population of people with T2D in Türkiye was associated with improved or maintained glycemic control.https://doi.org/10.1186/s13098-025-01918-yInsulin degludec/aspartat coformulationReusable insulin pensCarbon footprintPlastic wasteSustainabilityDiabetic waste |
| spellingShingle | Sezin Dogan Çakır Hatice Deniz Yücel Zeynep Akgül Kızılçay Mine Adaş Switching to insulin degludec/aspart penfill reusable cartridges in patients with type 2 diabetes mellitus: real-life outcomes Diabetology & Metabolic Syndrome Insulin degludec/aspartat coformulation Reusable insulin pens Carbon footprint Plastic waste Sustainability Diabetic waste |
| title | Switching to insulin degludec/aspart penfill reusable cartridges in patients with type 2 diabetes mellitus: real-life outcomes |
| title_full | Switching to insulin degludec/aspart penfill reusable cartridges in patients with type 2 diabetes mellitus: real-life outcomes |
| title_fullStr | Switching to insulin degludec/aspart penfill reusable cartridges in patients with type 2 diabetes mellitus: real-life outcomes |
| title_full_unstemmed | Switching to insulin degludec/aspart penfill reusable cartridges in patients with type 2 diabetes mellitus: real-life outcomes |
| title_short | Switching to insulin degludec/aspart penfill reusable cartridges in patients with type 2 diabetes mellitus: real-life outcomes |
| title_sort | switching to insulin degludec aspart penfill reusable cartridges in patients with type 2 diabetes mellitus real life outcomes |
| topic | Insulin degludec/aspartat coformulation Reusable insulin pens Carbon footprint Plastic waste Sustainability Diabetic waste |
| url | https://doi.org/10.1186/s13098-025-01918-y |
| work_keys_str_mv | AT sezindogancakır switchingtoinsulindegludecaspartpenfillreusablecartridgesinpatientswithtype2diabetesmellitusreallifeoutcomes AT haticedenizyucel switchingtoinsulindegludecaspartpenfillreusablecartridgesinpatientswithtype2diabetesmellitusreallifeoutcomes AT zeynepakgulkızılcay switchingtoinsulindegludecaspartpenfillreusablecartridgesinpatientswithtype2diabetesmellitusreallifeoutcomes AT mineadas switchingtoinsulindegludecaspartpenfillreusablecartridgesinpatientswithtype2diabetesmellitusreallifeoutcomes |